RxDoctor Payments Data

Amanda Tauscher, MD

Dermatology · Olathe, KSNPI 1841210770

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $602 of the $702 with a category attached, or 85.8%. 15 manufacturers reported payments, led by AbbVie at 28.5% of the total. That places this record below the midpoint for dermatology clinicians in KS, where the typical reported total is $1,741.

$702in general payments, 2019–2025

Across 23 payments — averaging $30.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$200
  • Sanofi-aventis U.S. LLC$100
  • UCB, Inc.$53
  • Incyte Corporation$49
  • LEO Pharma Inc.$44
  • Galderma Laboratories, L.p.$37
  • plus $218 from 9 others

What the payments were for

  • Food & beverage$60286%
  • Education$10014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$702 in reported general payments places this provider in the 30th percentile of 82 dermatology providers in Kansas.

See all dermatology providers in Kansas

Medicare billing

Part B allowed, 2024
$289,553
Medicare patients
1,072
Services billed
5,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast21$102,028
Cosentyx Sensoready (2 Pens)Secukinumab12$87,481
Humira(Cf)Adalimumab12$81,738
Dupixent SyringeDupilumab11$41,978
Clobetasol Propionate156$5,499
Desonide48$2,212
ValacyclovirValacyclovir Hcl48$1,643
Metronidazole36$1,612
Fluorouracil26$1,588
Triamcinolone Acetonide117$1,251
Dapsone11$1,217
Doxycycline Hyclate35$1,155
Minoxidil118$1,086
Fluocinonide41$1,033
Ciclopirox11$731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$24$102,02821 claims
AbbVieHumira(Cf)$200$81,73812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 82 dermatology providers in Kansas.

Other dermatology in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →